Research Antibodies And Reagents Market - Global Opportunity Analysis And Industry Forecast (2018-2023)
|発行||Meticulous Market Research Pvt. Ltd.||商品コード||607591|
|出版日||ページ情報||英文 321 Pages
|世界の研究用抗体・試薬市場：機会分析と産業予測 Research Antibodies And Reagents Market - Global Opportunity Analysis And Industry Forecast (2018-2023)|
|出版日: 2018年01月31日||ページ情報: 英文 321 Pages||
Research Antibodies and Reagents Market by Product (Reagents And Research Antibodies), By Technology (Western Blotting, Immunofluorescence, Immunosorbent Assays, Flow Cytometry, Immunohistochemistry, and Immunoprecipitation), by Application (Proteomics, Drug Discovery & Development, and Genomics), and by End User (Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, and Contract Research Organizations)- Global Opportunity Analysis and Industry Forecast to 2023
Global research antibodies and reagents market is expected to reach USD 13,276.5 million by 2023, at a CAGR of 6.5% during the forecast period of 2018 to 2023.
Succeeding an extensive secondary and primary research on research antibodies & reagents and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges in the market. Growing proteomics and genomics research studies, increasing funding for various research activities, and growing industry-academia collaborations are the key factors expected to propel the industry growth during the forecast period.
Traditionally, researchers were using conventional technologies such as Sanger's to sequence and analyze single gene, amplicon targets, genomic fragments, and short tandem repeats. However, it proved to be time consuming, less accurate, and low throughput technique for proteomics and genomics research. To overcome these drawbacks, researchers developed antibody based technologies for high throughput, accuracy, and more specificity. The various government authorities are supporting this R&D growth by providing funding and reducing approval time for new drug molecules.
Also, increasing industry-academia collaboration expands the relevance of research carried out in public institutions, thereby increasing the commercialization of public R&D outcomes, and the mobility in both private & public sector. Moreover, rising demand for protein therapeutics and personalized medicines, growing investment and focus on stem cell research, need for new biomarker identification, and increasing contribution from emerging economies provide significant opportunities in the research antibodies and reagents market. However, factors such as high cost with more developmental time for potential antibodies is expected to hinder the growth of this market to some extent. In addition, the issues related to quality and stability of research antibodies and intense pricing pressure on leading market players poses a great challenge for the various stakeholders in this market.
The study offers a comprehensive analysis of research antibodies and reagents market with respect to various products, technologies, applications, and end users. The research antibodies and reagents market is segmented on the basis of product, (reagents and research antibodies), technology, (western blotting, immunofluroscence, immunosorbent assays, flow cytometry, immunohistochemistry, immunoprecipitation, and others), application (proteomics, drug discovery & development, and genomics), and end user (pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations). The reagents commanded the largest share in the global research antibodies and reagents market in 2017, mainly attributed to high demand for various reagents in many routine assays and techniques with increased spending on research & development.
Further, an in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, and government & private investments. The geographic analysis section also comments on the key market players, shaping the growth of the industry in the respective countries. Geographically, North America commanded the largest share in the global research antibodies and reagents market in 2017, mainly due to the well-established healthcare system in the region, higher acceptance of advanced technologies, raising non-communicable diseases, increasing drug discovery programs & related rise in pharmaceutical R&D, rising focus on proteomics and genomics research, availability of research funding, and presence of many key players in this market.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017). The key players in the global research antibodies and reagents market are GE Healthcare (U.S.), Merck & Co., Inc.(U.S.), Thermo Fisher Scientific Inc.(U.S.), Amgen Inc.(U.S.), Sanofi (France), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc.(U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc.(U.S.), Eli Lilly and Company (U.S.), Becton Dickinsonand Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc.(U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc.(U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc.(U.S.), BioLegend, Inc.(U.S.), Abcam PLC (U.K.), and Cell Signaling Technology, Inc.(U.S.).